Stemline Therapeutics Inc. | Mutual Funds
Mutual Funds that own Stemline Therapeutics Inc.
Fidelity Select Biotechnology Portfolio
1,553,548
5.01%
0
0.28%
07/31/2018
Polar Capital Funds Plc - Healthcare Opportunities Fund
1,285,469
4.15%
102,640
1.26%
07/31/2018
Fidelity Small Cap Growth Fund
760,973
2.46%
-5,027
0.28%
04/30/2018
Vanguard Total Stock Market Index Fund
732,995
2.37%
0
0%
07/31/2018
Catalyst Eventide Gilead Fund
676,400
2.18%
0
0.62%
06/29/2018
Polar Capital Funds Plc - Biotechnology Fund
650,000
2.1%
50,000
2.25%
07/31/2018
SPDR S&P Biotech ETF
617,749
1.99%
1,590
0.18%
09/06/2018
iShares Russell 2000 ETF
578,341
1.87%
-309
0.02%
09/06/2018
AXA Framlington Biotech Fund
564,504
1.82%
-49,147
1.36%
02/28/2018
Eventide Healthcare & Life Sciences Fund
410,000
1.32%
0
1.01%
06/29/2018
| Address |
750 Lexington Avenue
New York New York 10022
United States
|
|
Employees
|
- |
| Website |
http://www.stemline.com |
| Updated |
07/08/2019 |
| Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies. |
